ArticleBioinorganic chemistry and applications2022
The Application of Natural Camel Milk Products to Treat Autism-Spectrum Disorders: Risk Assessment and Meta-Analysis of Randomized Clinical Trials.
Article in Bioinorganic chemistry and applications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.
- The Outcomes of Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2I) on Diabetes-Associated Neuropathy: A Systematic Review and meta-Analysis.Frontiers in pharmacology · 2022Pooled it
- Role of gastrointestinal health in managing children with autism spectrum disorder.World journal of clinical pediatrics · 2023Review
- Retracted: The Application of Natural Camel Milk Products to Treat Autism-Spectrum Disorders: Risk Assessment and Meta-Analysis of Randomized Clinical Trials.Bioinorganic chemistry and applications · 2023Article
- The Flourishing Camel Milk Market and Concerns about Animal Welfare and Legislation.Animals : an open access journal from MDPI · 2022Article
Corrections and comments
- Retraction · 2023-10-04Concerns/Issues about Data · Concerns/Issues about Results and/or Conclusions · Concerns/Issues about Referencing/Attributions · Concerns/Issues about Peer Review · Investigation by Journal/Publisher · Investigation by Third Party · Computer-Aided Content or Computer-Generated Content · Unreliable Results and/or Conclusions · · See also: https://pubpeer.com/publications/D25291A1D00C13285F8C745CB26D60
- Retracted
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Camel milk is better tolerated than the milk of other ruminants, potentially expanding its consumer appeal. It also contains essential vitamins, minerals, and immunoglobulins, providing the milk with antioxidant, antibacterial, and antiviral properties. These properties may reduce oxidative stress in camel milk consumers, ameliorating many conditions, including those of the CNS, such as autism spectrum disorders (ASDs). We performed a meta-analysis of randomized controlled trials (RCTs) in which camel milk administration (boiled or raw) was examined as an ASD treatment intervention. The primary endpoint was participants' total autism scores, determined using the Childhood Autistic Responsiveness Scale (CARS). A comparison of the responsiveness in these ASD intervention groups yielded a mean difference (MD) of 1.99 (0.89, 3.08) in those consuming boiled camel milk, MD = 2.77 (1.92, 3.61) in raw camel milk consumers, and MD = -1.02 (-0.10, 2.13) in cow milk consumers. Heterogeneity was notably low among the examined studies. Treatment of ASD with raw and boiled camel milk resulted in significantly lower CARS scores than the placebo. Our findings support the development of larger, more populated RCTs to establish camel milk's overall potential as a therapeutic intervention for CNS disorders.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.